Rheumatology

Filter

The first and only approved dual inhibitor of IL-17A and IL-17F1-6

February 2026

BIMZELX® Demonstrated Deep and Sustained Efficacy to 3 Years Across Multiple Disease Domains of PsA and the Full axSpA Spectrum…

First-Line Biologics Effective for Rheumatoid Arthritis and Kidney Disease

A study has shown the efficacy and safety of first-line biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis who suffer from chronic kidney disease

TNF Inhibitors Safe for Early and Late-Onset Ankylosing Spondylitis

A new study found that TNF inhibitors have similar rates of adverse events and treatment response in ankylosing spondylitis regardless of when the disease developed.

Ageing Population and Landscape of Rheumatoid Arthritis Treatment in Japan

An ageing society is characterised by the elderly population, classified as individuals aged 65 years or older, constituting ≥7% of…

Telerheumatology: What Should We Be Thinking About Now?

The present era of rheumatology is unmatched in history in terms of disease understanding, disease treatment, and disease discovery;…

The latest issue of EMJ Rheumatology

The new edition of EMJ Rheumatology features insights from this year’s European Alliance of Associations for Rheumatology Congress.

Review of the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress

THE European Alliance of Associations for Rheumatology (EULAR) 2024 Congress took place in Vienna, Austria, from June 12th–15th…

Effects of High-Intensity Resistance Training for Patients with Myositis

Reduced muscle endurance and strength are cardinal traits in patients with myositis. These traits are associated with reduced quality of…

Chimeric Antigen Receptor T Cell Therapy in Autoimmune Disease

HOT off the press from the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress was a session spotlighting the latest…

Loading posts...

« Previous 1 … 28 29 30 31 32 … 83 Next »